Phosphate binder dose adjustment in chronic kidney disease

The study of adjustment of phosphate binder dose based on phosphorus content of foods in controlling phosphorus level in children with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211119003

Enrollment

Registered

2021-11-19

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperphosphatemia and secondary hyperparathyroidism in children with chronic kidney disease stage III-V Phosphate binder, calcium carbonate, hyperphosphatemia, hyperparathyroidism, chronic kidney disease

Interventions

Dose adjusted per phosphate content of food, to take orally with meal and snack, 3 months study duration.

Experimental Drug

Calcium carbonate

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: Chronic kidney disease stage III-V Calcium carbonate use as phosphate binder for at least 12 weeks

Exclusion criteria

Exclusion criteria: 1. Calcium carbonate dosage adjustment in the past 12 weeks 2. Severe malnutrition 3. Serum calcium exceeding 11 mg/dL 4. Vitamin D deficiency 5. Use of calcium carbonate combined with other phosphate binder 6. Primary hyperparathyroidism 7. Acute kidney injury within the past 1 month

Design outcomes

Primary

Measure	Time frame
Hyperphosphatemia At the beginning and 12th week Serum phosphate	—

Secondary

Measure	Time frame
Hyperparathyroidism At the beginning and 12th week Serum parathyroid hormone level	—

Countries

Thailand

Contacts

Public ContactAnirut Pattaragarn

Siriraj hospital

anirut.pat@mahidol.edu0 2419 5660

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026